.svg){kind=small}
We are using conventional paper CRFs (so there is no worry for clients) which are then remotely entered into a database enabling us to produce tables and listings for safety review within two days of dosing. This is particularly useful in dose escalation studies as meaningful safety reviews can be developed within a very effective time frame.
-min.jpg)
.jpg)
Latest news
Single-dose gene silencing cure for fatal heart disease comes one step closer
March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read moreHow Does Social Time Contribute to a Positive Workplace Culture?
March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read moreEvents
ISA Symposium 2024
29-30 May 2024
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event
